Bristol-Myers Squibb Company logo

Bristol-Myers Squibb Company (BRM)

Market Closed
15 Jul, 20:00
XMUN XMUN
40. 51
+0.38
+0.95%
123.69B Market Cap
- P/E Ratio
2.4% Div Yield
0 Volume
- Eps
40.12
Previous Close
Day Range
40.51 40.51
Year Range
37.04 58.12
Want to track BRM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 16 days

Summary

BRM closed today higher at €40.51, an increase of 0.95% from yesterday's close, completing a monthly increase of 2.91% or €1.15. Over the past 12 months, BRM stock lost -25.8%.
BRM pays dividends to its shareholders, with the most recent payment made on May 01, 2025. The next announced payment will be in In 2 weeks on Aug 01, 2025 for a total of €0.62.
The last earnings report, released on Apr 25, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Jul 31, 2025.
Bristol-Myers Squibb Company has completed 6 stock splits, with the recent split occurring on Aug 07, 2001.
The company's stock is traded on 14 different exchanges and in various currencies, with the primary listing on NYSE (USD).

BRM Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends

Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends

The Dividend Harvesting Portfolio hit new all-time highs in value, profitability, and forward income, with a 29.58% return on invested capital. Consistent weekly investing, diversification, and a focus on income-producing assets have driven strong performance, even through volatile markets and macroeconomic headwinds. I see significant opportunities ahead, especially for big tech, REITs, and energy stocks, as the Fed's delayed rate cuts create a favorable environment.

Seekingalpha | 5 days ago
Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company

Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company

Bristol Myers Squibb is undervalued despite the looming patent cliff, as its robust pipeline and strong cash flow position it for future growth. The impact of Eliquis' patent expiry is overstated, since only half its revenue affects BMY's bottom line due to the Pfizer partnership. Earnings have been depressed by past acquisition amortizations, but these charges will drop sharply, revealing stronger profitability.

Seekingalpha | 5 days ago
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $47.66, denoting a +1.32% move from the preceding trading day.

Zacks | 6 days ago

Bristol-Myers Squibb Company Dividends

Bristol-Myers Squibb Company logo
BRM 1 weeks ago
Other
€0.53 Per Share
Bristol-Myers Squibb Company logo
BRM 3 months ago
Other
€0.53 Per Share
Bristol-Myers Squibb Company logo
BRM 6 months ago
Other
€0.53 Per Share
Bristol-Myers Squibb Company logo
BRM 9 months ago
Other
€0.51 Per Share
Bristol-Myers Squibb Company logo
BRM 5 Jul 2024
Other
€0.51 Per Share

Bristol-Myers Squibb Company Earnings

31 Jul 2025 (In 2 weeks) Date
1.35
Cons. EPS
-
EPS
25 Apr 2025 Date
-
Cons. EPS
-
EPS
24 Apr 2025 Date
-
Cons. EPS
-
EPS
6 Feb 2025 Date
-
Cons. EPS
-
EPS
31 Oct 2024 Date
-
Cons. EPS
-
EPS
Bristol-Myers Squibb Company logo
BRM 1 weeks ago
Other
€0.53 Per Share
Bristol-Myers Squibb Company logo
BRM 3 months ago
Other
€0.53 Per Share
Bristol-Myers Squibb Company logo
BRM 6 months ago
Other
€0.53 Per Share
Bristol-Myers Squibb Company logo
BRM 9 months ago
Other
€0.51 Per Share
Bristol-Myers Squibb Company logo
BRM 5 Jul 2024
Other
€0.51 Per Share
31 Jul 2025 (In 2 weeks) Date
1.35
Cons. EPS
-
EPS
25 Apr 2025 Date
-
Cons. EPS
-
EPS
24 Apr 2025 Date
-
Cons. EPS
-
EPS
6 Feb 2025 Date
-
Cons. EPS
-
EPS
31 Oct 2024 Date
-
Cons. EPS
-
EPS

Bristol-Myers Squibb Company (BRM) FAQ

What is the stock price today?

The current price is €40.51.

On which exchange is it traded?

Bristol-Myers Squibb Company is listed on NYSE.

What is its stock symbol?

The ticker symbol is BRM.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 2.4%.

What is its market cap?

As of today, the market cap is 123.69B.

What is the earnings per share?

The EPS is 1.35.

When is the next earnings date?

The next earnings report will release on Jul 31, 2025.

Has Bristol-Myers Squibb Company ever had a stock split?

Bristol-Myers Squibb Company had 6 splits and the recent split was on Aug 07, 2001.

Bristol-Myers Squibb Company Profile

Drug Manufacturers - General Industry
Healthcare Sector
Christopher S. Boerner CEO
XMUN Exchange
US1101221083 ISIN
US Country
34,100 Employees
3 Jul 2025 Last Dividend
7 Aug 2001 Last Split
- IPO Date

Overview

Bristol-Myers Squibb Company is an eminent global biopharmaceutical firm engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative biopharmaceutical products. With a spectrum of treatments covering hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases, the company has established a significant footprint in the healthcare sector. Initially founded as Bristol-Myers Company in 1887, it has evolved over the decades to become a leader in the biopharmaceutical industry, headquartered in Princeton, New Jersey. The company's operational reach spans globally, selling products through a diversified channel mix including wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Products and Services

  • Eliquis: Used for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
  • Opdivo: A versatile anti-cancer medication approved for a wide range of cancers including bladder, blood, colorectal, head and neck, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), lung, melanoma, mesothelioma, stomach, and esophageal cancer.
  • Pomalyst/Imnovid: Designed for the treatment of multiple myeloma, providing vital options for patients with this challenging form of cancer.
  • Orencia: Offers relief for individuals suffering from active rheumatoid arthritis and psoriatic arthritis, aiming to improve quality of life and reduce symptoms.
  • Sprycel: Specifically targeted at treating Philadelphia chromosome-positive chronic myeloid leukemia, a particular type of leukemia characterized by the presence of an abnormal chromosome.
  • Yervoy: This medication is used for the treatment of patients with unresectable or metastatic melanoma, offering a beam of hope for those battling this form of skin cancer.
  • Empliciti: Another option in the fight against multiple myeloma, providing an additional avenue for treatment for patients.
  • Abecma: Crafted for the treatment of relapsed or refractory multiple myeloma, Abecma offers a new horizon for patients who have not responded to previous treatments.
  • Reblozyl: A therapeutic option for the treatment of anemia, focusing on a condition that can severely impact the overall health and well-being of patients.
  • Opdualag: Specifically indicated for the treatment of unresectable or metastatic melanoma, enhancing the arsenal against this aggressive skin cancer.
  • Zeposia: Approved to treat relapsing forms of multiple sclerosis, this medication aims to reduce the frequency of relapses and slow the disease's progression.
  • Breyanzi: Used for the treatment of relapsed or refractory large B-cell lymphoma, Breyanzi provides a valuable tool in the fight against this type of cancer.
  • Onureg: A treatment option for acute myelogenous leukemia (AML), offering new hope for patients with this aggressive form of leukemia.
  • Inrebic: Targets myelofibrosis, a serious bone marrow disorder, by offering patients a chance for improved outcomes and symptom relief.
  • Camzyos: Focuses on the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), aimed at enhancing functional capacity and reducing symptoms in affected patients.
  • Sotyktu: Provides relief for patients suffering from moderate-to-severe plaque psoriasis, offering a new approach in managing this chronic skin condition.
  • Augtyro: Specifically developed for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), marking a significant step forward in targeted cancer therapy.
  • Revlimid: An oral immunomodulatory drug critical for the treatment of multiple myeloma, playing a key role in managing this form of cancer.
  • Abraxane: Used to treat breast cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer, Abraxane extends therapeutic options for patients facing these serious diseases.

Contact Information

Address: 430 East 29th Street
Phone: 212 546 4000